本帖最后由 老马 于 2013-3-13 13:43 编辑
/ G) ~5 v8 y) P" k7 {% z* {7 T4 y- `
健择(吉西他滨)+顺铂+阿瓦斯汀! C# ]0 f. [& R
Gemzar +Cisplatin + Avastin
& P3 Q; }; B ^9 ^! K& Z% s7 v- B8 Thttp://annonc.oxfordjournals.org/content/21/9/1804.full* ]6 J. y u5 U: b1 l
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 5 L' [4 s4 Y ?! D/ a* y( s1 X
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 u4 O. E/ Q, p) I& F: H( iResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 9 R$ b" h9 {0 H! l, z; f' u# E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 257)
1 h, ?# M- E8 |' W华为网盘附件:; h$ ~ Z ~2 @2 a. U/ N) g5 [
【华为网盘】ava.JPG; g! x1 g6 N8 R$ s2 i( z& T" p
|